Ages 3 to 11 Years

Molina Healthcare of Utah operates under an accelerated immunization schedule. In accordance to the Recommended Childhood and Adolescent Immunization Schedule from CDC, an accelerated schedule has been recommended in order to boost immunization rates and get children vaccinated on time. Such schedules have been adopted in California, Idaho, Oklahoma, Kansas, New Mexico and now Utah with much success. Molina encourages the use of the accelerated schedule in hopes to get children "Done by One".

PDF icon Immunization Timing Chart

Screening/ImmunizationScreening/Immunization
Height, weight, blood pressurePeriodically Height And Weight plotted on growth chart or BMI calculated at office visit.
Screen for amblyopia and strabismus. At 3-4 years.
Vision,objective by standard testing methodAt 3, 4, 5, 6, 8, and 10 years
Vision, subjective by historyAt 11 years
Hearing, subjective by history At 3 and 11 years
Hearing, objective by standard testing method.At 4, 5, 6, 8 and 10 years
1Hematocrit,for anemia or polycythemiaAt 15 months – 5 years for high risk for iron deficiency
14DTaP(diptheria, tetanus, acellular pertussis)At 4-6 years
IPV(inactivated polio virus)At 4-6 years
11Hepatitis A vaccination, if not previously immunized2doses at least 6 months apart
3Varicella(chicken pox)Once for healthy children who have not had a history of varicella infection orimmunization
13MMR(measles, mumps, rubella)At 4-6 years
17 MeningococcalvaccineRoutine administration at age 11
16Pneumococcal Conjugate (Prevnar)For high-risk children or if not previously vaccinated, refer to Note 16. 
2Hepatitis B vaccination, if not previouslyimmunized.At current visit, second dose at 4 weeks after first dose; thirddose at 8 weeks after second dose.
14Td booster (tetanus, diphtheria)At 11-12 years if at least 5 years since last dose.
6Influenza VaccinationFor children at increased risk of complication or transmission to high-risk persons.  Annually in Fall or Winter.
Additional Recommendations
9TB Screening - To be performed for high-risk population and in accordance with state law.
Depression Screening –  High risk population
Dental Referral
Obesity – promote healthy eating patterns and physical activity.
Order fluoride supplementation based on fluoride concentration of patient’s water supply(less than 0.6 ppm)
Domestic Violence screening
 
Counseling
Nutrition with counseling to maintain caloric balance, Injury Prevention, Car Seat, Seatbelt and Bicycle HelmetUse, Violence Prevention, Substance Avoidance (Tobacco, Alcohol, drugs), Dental Health, Regular Physical Activity to prevent coronary artery disease, hypertension, obesity and diabetes.
Notes
1.Hematocrit See AAP Nutrition Handbook (1998) for a discussion of universal and selective screening options. Consider earlier screening for high-risk infants (e.g. premature and low birth weight). See also Recommendations to Prevent and Control Iron Deficiency in the United Sates. MMWR. 1998: 47 (RR-3): 1-29.
14.Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15 to `18 months. The final dose in the series should be given at age >4 years.
11.Hepatitis A vaccine is recommended for children and adolescents in selected states and regions and for certain high-risk groups; consult your local public health authority. Children and adolescents in these states, regions and high-risk groups who have not been immunized against hepatitis A can begin the immunization series during any visit. The 2 doses in the series should be administered at least 6 months apart. See MMWR 1999; 48(RR-12); 1-37
3.Varicella vaccine is recommended at any visit on or after the first birthday for susceptible children, i.e., those who lack a reliable history of chickenpox and who have not been immunized. Susceptible persons age 13 or older should receive two doses at least 4 weeks apart.
17.Meningococcal vaccine CDC recommendations are for routine immunization for patients age 11years and for patients age 15 years who have not been previously vaccinated. Immunization also recommended for high risk patients including: college freshman living in dormitories, microbiologists who are routinely exposed to N. meningitdis isolates, military recruits, persons living in or traveling to countries in which N. meningitdis is hyperendemic or epidemic, persons who have terminal complement deficiencies, persons who have anatomic or functional asplenia. MMWR May 27, 2005. Volume 54, No. RR-7 (1-17).
16.Pneumococcal vaccine. The Heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2 to 23 months. It is also recommended for certain children age 24 to 59 months. The final dose in the series should be given at age >12 months.
2.Hepatitis B (HepB) vaccine. All infants should receive the first dose of hepatitis B vaccine soon after birth and before hospital discharge; the first dose may also be given by age 2 months if the infant’s mother is hepatitis B surface antigen (HBsAg) negative. Only monovalent HepB can be used for the birth dose. Monovalent or combination vaccine containing HepB may be used to complete the series. Four doses of vaccine may be administered when a birth dose is given. The second dose should be given at least 4 weeks after the first dose, except for combination vaccines, which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose. The last dose in the vaccination series (third or fourth dose) should not be administered before age 24 weeks.
6.Influenza vaccine. For Children and Adolescents influence vaccine is recommended annually for children aged ≥6 months with certain risk factors (including but not limited to asthma, cardiac disease, sickle cell disease, HIV and diabetes. In addition, healthy children ages 6-23 months and close contacts of healthy children ages 0-23 months are recommended to receive influenza vaccine, because children in this age group are at substantially increased risk for influenza-related hospitalizations. Children receiving trivalent inactivated influenza vaccine (TIV) should be administered a dosage appropriate for their age (0.25 mL if 6-35 months or 0.5 mL if ≥3 years). Children aged ≤8 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by at least 4 weeks for TIV and at least 6 weeks for live, attenuated influenza vaccine [LAIV]).
9.

Tuberculosis screening – The AAFP strongly recommends screening for tuberculosis by applying the mantoux test to patients at high risk for tuberculosis, including those with close contacts to a person with known or suspected TB, health care workers, immigrants from countries with high TB prevalence, HIV positive individuals, alcoholics, injection drug users, residents of long term care facilities, and medically underserved low income people.

13.Measles, mumps and rubella vaccine (MMR). The second dose of MMR is recommended routinely at age 4 to 6 years but may be administered during any visit, provided at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by the 11 to12 year old visit.
Measles Component: Adults born before 1957 may be considered immune to measles. Adults born in or after 1957 should receive at least one dose of MMR unless they have a medical contraindication, documentation of at least one dose or other acceptable evidence of immunity. A second dose of MMR is recommended for adults who are recently exposed to measles or in an outbreak setting; were previously vaccinated with killed measles vaccine; were vaccinated with an unknown vaccine between 1963 and 1967; are students in post-secondary educational institutions; work in health care facilities; plan to travel internationally.

PDF icon Adobe Acrobat Reader is required to view the file(s) above. a free version.

back to top